American Association for Cancer Research
crc-22-0298-s02.pdf (1.34 MB)

Figure S2 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer

Download (1.34 MB)
journal contribution
posted on 2023-04-04, 01:41 authored by Duncan R. McKenzie, Rosalind Graham, Thomas Lechmere, Clara Domingo-Vila, Thanussuyah Alaguthurai, Celeste Arman, Emily Pollock, Charalampos Gousis, Helen Kakkassery, Esme Carpenter, Ashwini Kurshan, Jennifer Vidler, Austin Kulasekararaj, Piers Patten, Bernard V. North, Timothy Tree, Katie J. Doores, Adrian C. Hayday, Sheeba Irshad

S2. T cell responses prior to SARS-CoV-2 vaccination dose 3.


Cancer Research UK (CRUK)

Leukemia and Lymphoma Society (LLS)

King's Health Partners | Guy's and St Thomas' NHS Foundation Trust

Wellcome Trust (WT)

Rosetrees Trust (Rosetrees)



Global health policy reliant on SARS-CoV-2 vaccine effectiveness is underpinned by our understanding of the durability of protection offered by sequential vaccinations and the efficacy of boosting, especially in immunocompromised patient populations who might constitute virus reservoirs. Here, we have: (i) clarified in patients with cancer the degree of waning of antibodies, serum neutralization titres against parental virus and variants of concern, and T-cell responses; (ii) evaluated the immune response among patients with cancer to a third dose of COVID-19 vaccine; and (iii) provided safety data following the third dose of the BNT162b2 COVID-19 vaccine in patients with cancer.